Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CXCR4 inhibitor GPC-100

An inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential hematopoietic stem cell (HSC)-mobilizing activity. Upon administration, CXCR4 inhibitor GPC-100 targets and binds to CXCR4, thereby preventing the binding of stromal-cell derived factor-1 (SDF-1; C-X-C motif chemokine ligand 12; CXCL12) to CXCR4. This results in HSC release from the bone marrow and HSC movement into the peripheral circulation. The CXCL12/CXCR4 signaling pathway plays an important role in the migration and retention of HSC in the bone marrow.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	GPC 100 GPC-100 GPC100

CXCR4 inhibitor GPC-100

Search NCI's Drug Dictionary